Mesoblast (MSB) Q4 2026 earnings summary

Executive summary

• RyoncilⓇ achieved net revenue of US $36 million for the quarter and US $115 million for the full year ended June 30, 2026, surpassing initial projections.

• Strong uptake of RyoncilⓇ since launch, with continued momentum expected in the coming fiscal year, especially across major U.S. pediatric centers.

• RyoncilⓇ is the first FDA-approved mesenchymal stromal cell (MSC) product for any indication and the only FDA-approved therapy for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).

Financial highlights

• Net revenue for the fourth quarter was US $36 million.

• Full-year net revenue reached US $115 million.

• Revenue growth has exceeded initial company projections.

Outlook and guidance

• Continued revenue growth anticipated in the next fiscal year, supported by strong product momentum.

• Operational activities are well funded through revenue growth and a new five-year facility.